Compare Centrus Energy Corp (LEU) vs 10X Genomics Inc (TXG) Price & Performance

Centrus Energy (LEU) trades at $143.88, down 2.22% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18) but maintains profitability with 10.23% net margins. Recent news highlights Centrus' strategic position as the only US-licensed HALEU producer, benefiting from nuclear energy growth and Russian uranium import bans.

The investment case balances high growth potential in nuclear fuel supply against execution risks and premium valuation. Analyst consensus at $218.10 suggests 52% upside, but technical indicators and recent equity dilution from a $500 million offering present near-term headwinds. Success depends on contract execution and nuclear industry adoption timelines.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.